Jacob M. Hooker, PhD
Massachusetts General Hospital
Massachusetts General Hospital
Phone: (617) 726-6596
Jacob M. Hooker, PhD
Massachusetts General Hospital
EDUCATIONAL TITLES
Publications from Harvard Catalyst Profiles
- Antonelli R, Jiménez C, Riley M, Servidei T, Riccardi R, Soriano A, Roma J, Martínez-Saez E, Martini M, Ruggiero A, Moreno L, Sánchez de Toledo J, Gallego S, Bové J, Hooker JM, Segura MF. CN133, a Novel Brain-Penetrating Histone Deacetylase Inhibitor, Hampers Tumor Growth in Patient-Derived Pediatric Posterior Fossa Ependymoma Models. Cancers (Basel) 2020. PubMed
- Osko JD, Porter NJ, Narayana Reddy PA, Xiao YC, Rokka J, Jung M, Hooker JM, Salvino JM, Christianson DW. Exploring Structural Determinants of Inhibitor Affinity and Selectivity in Complexes with Histone Deacetylase 6. J Med Chem 2019. PubMed
- Gerstner E, Emblem KE, Chang K, Vakulenko-Lagun B, Yen YF, Beers AL, Dietrich J, Plotkin SR, Catana C, Hooker JM, Duda DG, Rosen B, Kalpathy-Cramer J, Jain RK, Batchelor T. Bevacizumab reduces permeability and concurrent temozolomide delivery in a subset of patients with recurrent glioblastoma. Clin Cancer Res 2019. PubMed
- Porter NJ, Osko JD, Diedrich D, Kurz T, Hooker JM, Hansen FK, Christianson DW. Histone Deacetylase 6-Selective Inhibitors and the Influence of Capping Groups on Hydroxamate-Zinc Denticity. J Med Chem 2018; 61:8054-8060. PubMed
- Larimer BM, Dubois F, Bloch E, Nesti S, Placzek M, Zadra G, Hooker JM, Loda M, Mahmood U. Specific F-FDHT Accumulation in Human Prostate Cancer Xenograft Murine Models is Facilitated by Pre-Binding to Sex Hormone Binding Globulin. J Nucl Med 2018. PubMed
- Schuetze KB, Stratton MS, Blakeslee WW, Wempe MF, Wagner FF, Holson EB, Kuo YM, Andrews AJ, Gilbert TM, Hooker JM, McKinsey TA. Overlapping and Divergent Actions of Structurally Distinct HDAC Inhibitors in Cardiac Fibroblasts. J Pharmacol Exp Ther 2017. PubMed
- Ricq EL, Hooker JM, Haggarty SJ. Activity-Dependent Regulation of Histone Lysine Demethylase KDM1A by a Putative Thiol/Disulfide Switch. J Biol Chem 2016. PubMed
- Wey HY, Gilbert TM, Zürcher NR, She A, Bhanot A, Taillon BD, Schroeder FA, Wang C, Haggarty SJ, Hooker JM. Insights into neuroepigenetics through human histone deacetylase PET imaging. Sci Transl Med 2016; 8:351ra106. PubMed
- Wey HY, Wang C, Schroeder FA, Logan J, Price JC, Hooker JM. Kinetic Analysis and Quantification of [¹¹C]Martinostat for in Vivo HDAC Imaging of the Brain. 2015. PubMed
- Wang C, Schroeder FA, Wey HY, Borra R, Wagner FF, Reis S, Kim SW, Holson EB, Haggarty SJ, Hooker JM. In vivo imaging of histone deacetylases (HDACs) in the central nervous system and major peripheral organs. J Med Chem 2014; 57:7999-8009. PubMed
- Seo YJ, Kang Y, Muench L, Reid A, Caesar S, Jean L, Wagner F, Holson E, Haggarty SJ, Weiss P, King P, Carter P, Volkow ND, Fowler JS, Hooker JM, Kim SW. Image-guided synthesis reveals potent blood-brain barrier permeable histone deacetylase inhibitors. 2014; 5:588-96. PubMed
- Diyabalanage HV, Van de Bittner GC, Ricq EL, Hooker JM. A chemical strategy for the cell-based detection of HDAC activity. ACS Chem Biol 2014; 9:1257-62. PubMed
- Seo YJ, Muench L, Reid A, Chen J, Kang Y, Hooker JM, Volkow ND, Fowler JS, Kim SW. Radionuclide labeling and evaluation of candidate radioligands for PET imaging of histone deacetylase in the brain. Bioorg Med Chem Lett 2013; 23:6700-5. PubMed
- Kim SW, Hooker JM, Otto N, Win K, Muench L, Shea C, Carter P, King P, Reid AE, Volkow ND, Fowler JS. Whole-body pharmacokinetics of HDAC inhibitor drugs, butyric acid, valproic acid and 4-phenylbutyric acid measured with carbon-11 labeled analogs by PET. Nucl Med Biol 2013; 40:912-8. PubMed
- Schroeder FA, Chonde DB, Riley MM, Moseley CK, Granda ML, Wilson CM, Wagner FF, Zhang YL, Gale J, Holson EB, Haggarty SJ, Hooker JM. FDG-PET imaging reveals local brain glucose utilization is altered by class I histone deacetylase inhibitors. Neurosci Lett 2013; 550:119-24. PubMed
- Diyabalanage HV, Granda ML, Hooker JM. Combination therapy: histone deacetylase inhibitors and platinum-based chemotherapeutics for cancer. Cancer Lett 2013. PubMed
- Schroeder FA, Lewis MC, Fass DM, Wagner FF, Zhang YL, Hennig KM, Gale J, Zhao WN, Reis S, Barker DD, Berry-Scott E, Kim SW, Clore EL, Hooker JM, Holson EB, Haggarty SJ, Petryshen TL. A selective HDAC 1/2 inhibitor modulates chromatin and gene expression in brain and alters mouse behavior in two mood-related tests. PLoS ONE 2013; 8:e71323. PubMed
- Wang C, Eessalu TE, Barth VN, Mitch CH, Wagner FF, Hong Y, Neelamegam R, Schroeder FA, Holson EB, Haggarty SJ, Hooker JM. Design, synthesis, and evaluation of hydroxamic acid-based molecular probes for in vivo imaging of histone deacetylase (HDAC) in brain. Am J Nucl Med Mol Imaging 2013; 4:29-38. PubMed
- Hooker JM, Kim SW, Reibel AT, Alexoff D, Xu Y, Shea C. Evaluation of [(11)C]metergoline as a PET radiotracer for 5HTR in nonhuman primates. Bioorg Med Chem 2010; 18:7739-45. PubMed
- Schönberger M, Leggett C, Kim SW, Hooker JM. Synthesis of [11C]SSR149415 and preliminary imaging studies using positron emission tomography. Bioorg Med Chem Lett 2010; 20:3103-6. PubMed
- Biegon A, Kim SW, Logan J, Hooker JM, Muench L, Fowler JS. Nicotine blocks brain estrogen synthase (aromatase): in vivo positron emission tomography studies in female baboons. Biol Psychiatry 2010; 67:774-7. PubMed
- Liu L, Xu Y, Shea C, Fowler JS, Hooker JM, Tonge PJ. Radiosynthesis and bioimaging of the tuberculosis chemotherapeutics isoniazid, rifampicin and pyrazinamide in baboons. J Med Chem 2010; 53:2882-91. PubMed
- Hooker JM. Modular strategies for PET imaging agents. Curr Opin Chem Biol 2010; 14:105-11. PubMed
- Hooker JM, Kim SW, Alexoff D, Xu Y, Shea C, Reid A, Volkow N, Fowler JS. Histone deacetylase inhibitor, MS-275, exhibits poor brain penetration: PK studies of [C]MS-275 using Positron Emission Tomography. 2010; 1:65-73. PubMed
- Hooker JM, Munro TA, Béguin C, Alexoff D, Shea C, Xu Y, Cohen BM. Salvinorin A and derivatives: protection from metabolism does not prolong short-term, whole-brain residence. Neuropharmacology 2009; 57:386-91. PubMed
- Volkow ND, Fowler JS, Logan J, Alexoff D, Zhu W, Telang F, Wang GJ, Jayne M, Hooker JM, Wong C, Hubbard B, Carter P, Warner D, King P, Shea C, Xu Y, Muench L, Apelskog-Torres K. Effects of modafinil on dopamine and dopamine transporters in the male human brain: clinical implications. JAMA 2009; 301:1148-54. PubMed
- Hooker JM, Reibel AT, Hill SM, Schueller MJ, Fowler JS. One-pot, direct incorporation of [11C]CO2 into carbamates. Angew Chem Int Ed Engl 2009; 48:3482-5. PubMed
- Hooker JM, Xu Y, Schiffer W, Shea C, Carter P, Fowler JS. Pharmacokinetics of the potent hallucinogen, salvinorin A in primates parallels the rapid onset and short duration of effects in humans. Neuroimage 2008; 41:1044-50. PubMed
- Datta A, Hooker JM, Botta M, Francis MB, Aime S, Raymond KN. High relaxivity gadolinium hydroxypyridonate-viral capsid conjugates: nanosized MRI contrast agents. J Am Chem Soc 2008; 130:2546-52. PubMed
- Hooker JM, Schönberger M, Schieferstein H, Fowler JS. A simple, rapid method for the preparation of [11C]formaldehyde. Angew Chem Int Ed Engl 2008; 47:5989-92. PubMed
- Hooker JM, Datta A, Botta M, Raymond KN, Francis MB. Magnetic resonance contrast agents from viral capsid shells: a comparison of exterior and interior cargo strategies. Nano Lett 2007; 7:2207-10. PubMed
- Johnson HR, Hooker JM, Francis MB, Clark DS. Solubilization and stabilization of bacteriophage MS2 in organic solvents. Biotechnol Bioeng 2007; 97:224-34. PubMed
- Hooker JM, Esser-Kahn AP, Francis MB. Modification of aniline containing proteins using an oxidative coupling strategy. J Am Chem Soc 2006; 128:15558-9. PubMed
- Hooker JM, Patel V, Kothari S, Schiffer WK. Metabolic changes in the rodent brain after acute administration of salvinorin A. Mol Imaging Biol ; 11:137-43. PubMed
- Hooker JM, O'Neil JP, Romanini DW, Taylor SE, Francis MB. Genome-free viral capsids as carriers for positron emission tomography radiolabels. Mol Imaging Biol ; 10:182-91. PubMed
- Kovacs EW, Hooker JM, Romanini DW, Holder PG, Berry KE, Francis MB. Dual-surface-modified bacteriophage MS2 as an ideal scaffold for a viral capsid-based drug delivery system. Bioconjug Chem ; 18:1140-7. PubMed
- Gerstner ER, Emblem KE, Yen YF, Dietrich J, Jordan JT, Catana C, Wenchin KL, Hooker JM, Duda DG, Rosen BR, Kalpathy-Cramer J, Jain RK, Batchelor TT. Vascular dysfunction promotes regional hypoxia after bevacizumab therapy in recurrent glioblastoma patients. ; 2:vdaa157. PubMed